How Tassé was paid
$3.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Daniel TasséChief Executive Officer and Director | $600,000 | $780,000 | — | $1,915,376 | $62,571 | $3,357,947 |
| Virginie BoucinhaChief Financial Officer | $350,446 | $249,698 | $86,415 | $381,486 | — | $1,068,045 |
| Pharis MohideenChief Medical Officer | $590,787 | $430,219 | $118,820 | $502,687 | — | $1,642,513 |
What changed and why
- $3.4M$3,357,947 was the CEO’s total compensation in 2025 versus $1,622,146 in 2024.
- $1.9M$1,915,376 of the CEO’s 2025 compensation was option awards, compared with $488,126 in 2024.
- 130%130% of corporate objectives were achieved for 2025 under the annual incentive program.
- $67,455$67,455 of Virginie Boucinha’s bonus was exceptional compensation tied to successful PIPE financing.
- $114K$113,557 of Pharis Mohideen’s bonus was exceptional compensation tied to successful PIPE financing.
- The long-term incentive program uses a mix of restricted share units and stock options.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.